Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up2.770 +0.030 (+1.095%)
Research Report

01/12/2020 14:23

{I-bank focus}Nomura cuts Sino Biopharm (01177) to HK$8.97

[ET Net News Agency, 1 December 2020] Nomura lowered its target price for Sino
Biopharmaceutical (01177) to HK$8.97 from HK$11.6 and maintained its "buy" rating.
The research house said Sino Biopharm reported weak 3Q results, due to the lingering
impact of the pandemic, implementation of GPO (group purchasing organization) on old
blockbuster products and expenses on revamping the sales system.
Continued sales ramp-up of new generics and recovery of hospital market are likely to
lead to a rebound of sales in 1H 2021, Nomura said. Assuming the sales restructuring is
completed in 2021, it expects Sino Biopharm's revenue to record a 27% CAGR over 2021-23.
It expects underlying profit to grow at 23% annually over the period, slightly lower than
topline growth, considering rising R&D input. (KL)

Back to Research Report

Remark: Real time quote last updated: 26/04/2024 17:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.